Literature DB >> 30194500

Equivalent feasibility and safety of perioperative care by ERAS in open and laparoscopy-assisted distal gastrectomy for gastric cancer: a single-institution ancillary study using the patient cohort enrolled in the JCOG0912 phase III trial.

Toru Aoyama1,2, Takaki Yoshikawa3,4,5, Tsutomu Sato1,2, Tsutomu Hayashi1,2, Takanobu Yamada1,2, Takashi Ogata1, Haruhiko Cho1.   

Abstract

BACKGROUND: Laparoscopy-assisted distal gastrectomy (LADG) has an advantage of earlier recovery after surgery due to having lower invasiveness and wound pain than open distal gastrectomy (ODG). However, whether the same enhanced recovery after surgery (ERAS) program for LADG is equally feasible and safe for ODG remains unclear.
METHODS: We retrospectively extracted the clinical data of the patients enrolled in JCOG0912 from the medical record system of our hospital and compared the treatment process and short-term surgical outcomes between LADG and ODG. Our ERAS program consisted of 13 elements (4 preoperative, 4 intraoperative, and 5 postoperative elements). The morbidity was defined as complications of grade 2 or more.
RESULTS: One hundred and sixty-three patients were entered from our hospital and randomized to undergo ODG (82 patients) or LADG (81 patients). The patient's backgrounds, surgical outcomes, and pathological outcomes were similar between the ODG and LADG groups. The rate of completing the clinical pathway was 95.1% in both groups, and the rates of completing each ERAS element were similar. However, the additional use of acetaminophen was significantly more frequent in the ODG group than in the LADG group (18.3% vs. 6.2%, p = 0.03). The median hospital stay after surgery was 9 days in both groups. Morbidity, defined as Clavien-Dindo classification > grade 2, was observed in 6.1% of the ODG group and 11.1% of the LADG group. No mortality occurred in either group.
CONCLUSION: This study showed that the regimen of perioperative care performed by the ERAS program for LADG was equally feasible and safe for ODG with additional pain control. Less pain observed in LADG was not so apparent advantage for completion and safety of ERAS care.

Entities:  

Keywords:  ERAS; Laparoscopy-assisted distal gastrectomy; Open distal gastrectomy; Randomized

Mesh:

Year:  2018        PMID: 30194500     DOI: 10.1007/s10120-018-0873-3

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  5 in total

1.  A Nomogram for Prediction of Survival in Patients After Gastrectomy Within Enhanced Recovery After Surgery (ERAS): A Single-Center Retrospective Study.

Authors:  Yuqi Sun; Zequn Li; Xiaodong Liu; Shougen Cao; Xuechao Liu; Chuan Hu; Yulong Tian; Jianfei Xu; Daoshen Wang; Xin Zhou; Yanbing Zhou
Journal:  Med Sci Monit       Date:  2020-10-10

2.  Peripheral Lymphocyte Subsets Absolute Counts as Feasible Clinical Markers for Predicting Surgical Outcome in Gastric Cancer Patients After Laparoscopic D2 Gastrectomy: A Prospective Cohort Study.

Authors:  Ci Dian Dan Zeng; Yi Xin Tong; Ai Tang Xiao; Chun Gao; Sheng Zhang
Journal:  J Inflamm Res       Date:  2021-10-29

3.  Actual compliance rate of Enhanced Recovery After Surgery protocol in laparoscopic distal gastrectomy.

Authors:  Sang Hyeok Park; So Hyun Kang; Sang Jun Lee; Yongjoon Won; Young Suk Park; Sang-Hoon Ahn; Yun-Suhk Suh; Do Joong Park; Hyung-Ho Kim
Journal:  J Minim Invasive Surg       Date:  2021-12-15

4.  Study on the Risk Factors of Pulmonary Infection after Laparoscopic Surgery and Analysis of the Detection Results of Drug-Resistant Bacteria.

Authors:  Tingting Zhai; Liwei Zhang; Jing Sun; Yuanchun Li; Jie Hou; Fengxia Du
Journal:  J Healthc Eng       Date:  2022-03-18       Impact factor: 2.682

5.  Inflection-Point Nutrition Support Determined by Oral Mucosal Apoptosis Rate Is a Novel Assessment Strategy for Personalized Nutrition: A Prospective Cohort Study.

Authors:  Chun Gao; Zike Li; Sheng Zhang; Dengyi Cao; Yang Yu; Yujie Zhang; Hao Chen; Dehua Fu; Jianping Gong
Journal:  J Pers Med       Date:  2022-02-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.